Ortec Targeting Late 1999 Launch Of Cultured Skin Product Under HDE
This article was originally published in The Gray Sheet
Executive Summary
Ortec International is hoping to release its Composite Cultured Skin for the management of chronic ulcers in patients with junctional and dystrophic forms of epidermolysis bullosa in late 1999 following a recent humanitarian use designation from FDA.
You may also be interested in...
Bilayered Collagen Matrix Would Treat Venous Leg Ulcer, Autograft Wounds
Ortec will launch its OrCel wound care product for three FDA-cleared indications once the cryopreserved tissue gains marketing approval in the late spring for venous leg ulcer treatment, the firm says
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.